# Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)

> **NCT04142619** · PHASE1 · TERMINATED · sponsor: **Cellectis S.A.** · enrollment: 11 (actual)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** UCARTCS1A

## Key facts

- **NCT ID:** NCT04142619
- **Lead sponsor:** Cellectis S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-21
- **Primary completion:** 2023-06-18
- **Final completion:** 2023-06-18
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** The trial was discontinued due to sponsor's decision and not a consequence of any safety concern.
- **Last updated:** 2023-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04142619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04142619, "Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04142619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*